Quest Diagnostics Incorporated $DGX Shares Sold by Swiss National Bank

12 Mar 2026, 07:54 by Jessica Moore · The Cerbat Gem

Swiss National Bank cut its stake in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 4.8% during the third quarter, HoldingsChannel reports. The institutional investor owned 321,800 shares of the medical research company’s stock after selling 16,100 shares during the quarter. Swiss National Bank’s holdings in Quest Diagnostics were worth $61,329,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Lebenthal Global Advisors LLC lifted its holdings in Quest Diagnostics by 117.5% in the 3rd quarter. Lebenthal Global Advisors LLC now owns 5,034 shares of the medical research company’s stock valued at $959,000 after purchasing an additional 2,720 shares in the last quarter. Rakuten Investment Management Inc. purchased a new stake in shares of Quest Diagnostics during the third quarter worth $4,713,000. Pacer Advisors Inc. raised its position in shares of Quest Diagnostics by 2,531.6% in the third quarter. Pacer Advisors Inc. now owns 450,898 shares of the medical research company’s stock valued at $85,932,000 after buying an additional 433,764 shares during the last quarter. TKG Advisors LLC raised its position in shares of Quest Diagnostics by 125.1% in the third quarter. TKG Advisors LLC now owns 14,596 shares of the medical research company’s stock valued at $2,782,000 after buying an additional 8,112 shares during the last quarter. Finally, Cibc World Market Inc. lifted its stake in shares of Quest Diagnostics by 209.6% in the third quarter. Cibc World Market Inc. now owns 7,765 shares of the medical research company’s stock worth $1,480,000 after buying an additional 5,257 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Patrick Plewman sold 5,662 shares of the stock in a transaction that occurred on Tuesday, February 10th. The stock was sold at an average price of $204.00, for a total value of $1,155,048.00. Following the completion of the transaction, the senior vice president directly owned 15,381 shares in the company, valued at approximately $3,137,724. This represents a 26.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Karthik Kuppusamy sold 2,628 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $204.86, for a total value of $538,372.08. Following the sale, the senior vice president directly owned 13,441 shares of the company’s stock, valued at approximately $2,753,523.26. This trade represents a 16.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 24,083 shares of company stock valued at $4,945,262. Insiders own 8.16% of the company’s stock.

Quest Diagnostics Price Performance

Quest Diagnostics stock opened at $200.55 on Thursday. Quest Diagnostics Incorporated has a 12-month low of $157.20 and a 12-month high of $213.50. The stock has a market cap of $22.03 billion, a P/E ratio of 22.92, a PEG ratio of 2.59 and a beta of 0.66. The company has a 50-day moving average price of $193.23 and a 200 day moving average price of $186.15. The company has a current ratio of 1.04, a quick ratio of 0.96 and a debt-to-equity ratio of 0.72.

Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its earnings results on Tuesday, February 10th. The medical research company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.35 by $0.07. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.57%. The company had revenue of $2.81 billion for the quarter, compared to the consensus estimate of $2.75 billion. During the same period in the previous year, the firm earned $2.23 earnings per share. Quest Diagnostics’s quarterly revenue was up 7.1% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. Sell-side analysts anticipate that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current year.

Quest Diagnostics announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, February 10th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 4.7% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Quest Diagnostics Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, April 20th. Stockholders of record on Monday, April 6th will be given a dividend of $0.86 per share. This represents a $3.44 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Monday, April 6th. This is a boost from Quest Diagnostics’s previous quarterly dividend of $0.80. Quest Diagnostics’s dividend payout ratio is presently 39.31%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Weiss Ratings restated a “buy (b-)” rating on shares of Quest Diagnostics in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. Barclays raised their target price on shares of Quest Diagnostics from $210.00 to $225.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 11th. Evercore set a $220.00 price target on Quest Diagnostics in a research report on Wednesday, February 11th. Finally, Truist Financial increased their price target on Quest Diagnostics from $205.00 to $220.00 and gave the company a “hold” rating in a report on Wednesday, February 11th. Eight research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $210.29.

View Our Latest Stock Analysis on DGX

About Quest Diagnostics

(Free Report)

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.